How to Access PMDA Review Reports in English: The Definitive Guide

What PMDA Review Reports Contain

When PMDA approves a drug, it publishes a detailed review report (審査報告書) that documents the agency's complete scientific evaluation. These are not brief summaries — they are comprehensive documents, often running 100-300+ pages, that cover every aspect of the agency's assessment.

A typical PMDA review report includes:

• Product overview — Drug name (brand and generic), active ingredient, therapeutic class, indication, dosage and administration, applicant company, and approval date.
• Quality evaluation (CMC) — Assessment of drug substance and drug product quality, manufacturing process, specifications, stability data, and any quality-related conditions.
• Nonclinical evaluation— Review of pharmacology, pharmacokinetics, and toxicology studies. PMDA's assessment of the nonclinical safety profile and any concerns raised.
• Clinical efficacy evaluation— Detailed analysis of clinical trial data, including study design, patient populations, primary and secondary endpoints, statistical analyses, and PMDA's interpretation of the efficacy data.
• Clinical safety evaluation — Comprehensive review of adverse events, serious adverse events, deaths, laboratory abnormalities, and special populations (elderly, renally impaired, hepatically impaired).
• Risk-benefit assessment— PMDA's overall conclusion on whether the benefits outweigh the risks, including any conditions or requirements attached to the approval.
• Approval conditions — Post-marketing requirements such as post-marketing surveillance studies, risk management plans, and data reporting obligations.
• Expert discussion — Summary of deliberations by external experts consulted during the review, and their recommendations.

In many ways, PMDA review reports contain more granular clinical detailthan FDA approval packages. PMDA reviewers routinely include detailed questioning of the applicant's data interpretations, and the applicant's responses are documented within the report. This back-and-forth reveals regulatory thinking that is invaluable for companies planning their own submissions.

Why They Matter for Competitive Intelligence

PMDA review reports are not just regulatory documents — they are a goldmine of competitive intelligence. Here's why pharmaceutical companies, biotech firms, and consulting agencies seek them out:

• Understand PMDA's expectations — Learn exactly what data PMDA required for drugs in your therapeutic area, what questions reviewers asked, and what standards they applied.
• Benchmark your development program — Compare your clinical trial design, endpoints, and patient populations to what PMDA accepted (or challenged) for similar drugs.
• Identify approval conditions — Understand what post-marketing commitments PMDA imposed on competitors, which can signal areas of regulatory concern in your drug class.
• Inform Japan market entry strategy — For companies evaluating whether and how to enter the Japanese market, review reports reveal the actual data burden required — not just what guidelines say, but what PMDA actually demanded in practice.
• Cross-reference with FDA and EMA — Comparing how PMDA, FDA, and EMA evaluated the same drug reveals regulatory divergences. This is critical for global regulatory strategy, especially around dosing, labeling, and risk management.

PMDA's English Translation Program

PMDA recognized early on that Japanese-only review reports limited international transparency. In response, PMDA launched an English translation program for selected review reports — an initiative that has been running for over a decade.

Scope and History

PMDA began translating review reports into English in the early 2010s as part of its broader internationalization strategy. The program has grown over the years, and PMDA now routinely translates review reports for drugs that are considered globally significant or of high international interest.

The Limitation

Here is the critical problem: PMDA has only translated approximately 300 review reports into English out of thousands of approved drug products. The selection criteria are opaque — PMDA does not publish a clear policy on which reports get translated. In general, new molecular entities with global development programs are more likely to be translated, while generics, biosimilars, supplemental approvals, and Japan-only products are almost never translated.

Even for translated reports, there is typically a delay of 6-12 monthsbetween the Japanese publication and the English version appearing on PMDA's website. For competitive intelligence purposes, that lag can be commercially significant.

How to Find English Reports on PMDA's Website

If the report you need does have an English version, here is exactly how to find it on PMDA's website:

Step 1: Go to the PMDA English Portal

Navigate to https://www.pmda.go.jp/english/. This is PMDA's official English-language site.

Step 2: Access the Review Reports Database

From the top navigation, go to Review Services then New Drugs. Alternatively, navigate directly to the review reports page at PMDA Approved Information: Drugs.

Step 3: Search by Drug Name or Keyword

Use the search function to find your drug by brand name, generic name (INN), or active ingredient. The interface supports English keyword searches. Results will show the drug name, approval date, indication, and links to available documents.

Step 4: Check for the English Review Report Link

On the individual drug page, look for a link labeled "Review Report" or "Report on the Deliberation Results" in English. If an English translation exists, it will be available as a PDF download. If only Japanese documents are listed, no English translation is available for that product.

Step 5: Check the Annual Lists

PMDA also publishes annual lists of newly approved drugs with links to review materials. These lists are organized by fiscal year and can be browsed chronologically. However, these lists are not always consistently maintained in English.

What's NOT Available in English

This is where it gets frustrating for non-Japanese speakers. The vast majority of PMDA's regulatory data is only available in Japanese:

• Most review reports — Over 80% of review reports have no English translation. This includes most generics, biosimilars, supplemental indications, and many important new molecular entities.
• Package inserts (labels) — Japanese drug labels are published only in Japanese. There is no systematic English translation program for package inserts.
• Risk Management Plans (RMPs) — Published only in Japanese.
• Interview forms — These detailed product information documents, unique to Japan, are Japanese-only.
• PMDA safety communications — Post-market safety alerts and regulatory actions are published primarily in Japanese, with only selected notices translated to English.
• Consultation meeting outcomes — Pre-submission consultation guidance is not published in any language, but related regulatory guidance documents are predominantly in Japanese.

For a foreign company trying to understand the Japanese pharmaceutical landscape, this language barrier is one of the most significant practical obstacles. Hiring specialized regulatory translators is expensive and slow. Machine translation of technical regulatory Japanese is unreliable for critical details like dosing, adverse event data, and approval conditions.

How PharmaLens Solves This

PharmaLenswas built specifically to address this problem. Instead of relying on PMDA's limited English translations, PharmaLens provides a structured, searchable database of PMDA drug approval data — fully in English, updated daily.

What PharmaLens Provides

• 1,400+ approved drugs — Comprehensive coverage of PMDA-approved pharmaceutical products, not limited to the ~300 drugs with official English review reports.
• Structured data, not PDFs — Instead of hunting through 200-page PDF review reports, PharmaLens delivers structured fields: drug name, generic name, indication, approval date, applicant, therapeutic class, review timeline, and approval conditions — all searchable, filterable, and exportable.
• Daily updates — New PMDA approvals are captured and added to the database as they are published. No more waiting months for English translations.
• API access — For teams that need to integrate PMDA data into their own regulatory information systems, competitive intelligence platforms, or internal dashboards, PharmaLens offers API access to all data fields.
• Cross-reference capability — Link PMDA-approved drugs to their FDA and EMA counterparts. Quickly identify drugs approved in Japan but not yet approved in the US or EU, and vice versa.

Why Structured Data Beats PDF Translations

Even when English review reports exist, extracting actionable data from a 200-page PDF is time-consuming. Regulatory affairs professionals and competitive intelligence analysts need to quickly answer questions like:

• What drugs were approved in oncology in Japan last year?
• What were the approval conditions for the three most recent PD-1 inhibitors?
• How long did PMDA review take for drugs in my therapeutic area?
• Which drugs were approved in Japan before the US or EU?
• What bridging study requirements were applied to similar drugs?

With PharmaLens, these questions can be answered in seconds through search and filtering — instead of hours spent reading and cross-referencing multiple PDF documents.

Use Cases: Who Needs This Data and Why

Competitor Analysis

Monitor what competitors are getting approved in Japan, how quickly they are moving through PMDA review, and what conditions are being placed on their approvals. Track new indications, formulation changes, and biosimilar entries. PharmaLens makes it possible to set up systematic monitoring of your competitive landscape in Japan without reading Japanese.

Japan Market Entry Research

Before committing to a Japan filing, companies need to understand the regulatory landscape for their drug class. What data did PMDA require for similar drugs? Were bridging studies needed? What were the review timelines? PharmaLens provides this precedent data in a searchable format, helping BD&L teams and regulatory strategists make informed go/no-go decisions.

Cross-Reference Japan, FDA, and EMA Approvals

Global regulatory teams need to track how the same drug fares across different regulatory authorities. PharmaLens enables quick cross-referencing between PMDA, FDA, and EMA approvals — identifying discrepancies in indications, dosing, safety warnings, and approval timelines. This is particularly valuable for global labeling harmonization efforts and regulatory strategy planning.

Due Diligence for Licensing and M&A

When evaluating licensing-in opportunities or acquisition targets with Japan-approved products, having quick access to PMDA approval data is essential. PharmaLens allows BD&L teams to rapidly assess a product's regulatory status in Japan, including approval conditions, post-marketing requirements, and competitive positioning.

Academic and Consulting Research

Researchers studying regulatory science, drug access timelines, and cross-country regulatory comparisons rely on PMDA data. PharmaLens makes this data accessible to non-Japanese-speaking researchers for the first time at scale.

Get Started

PMDA review reports are among the most valuable — and most underutilized — sources of pharmaceutical regulatory intelligence in the world. The language barrier has kept this data locked away from most global teams for too long.

Whether you are a regulatory affairs professional preparing a Japan submission, a competitive intelligence analyst tracking the Japanese market, or a BD&L executive evaluating a Japan opportunity, having structured English access to PMDA data is no longer optional — it is a competitive necessity.

References

• PMDA: Approved Information on Drugs (English)
• PMDA: International Activities and English Publications
• PMDA: Drug Review Reports (Japanese portal)

Source: PMDA Website. This article is for informational purposes only and does not constitute regulatory advice.